{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T09:01:23Z","timestamp":1783587683933,"version":"3.55.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,4,12]],"date-time":"2023-04-12T00:00:00Z","timestamp":1681257600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,12]],"date-time":"2023-04-12T00:00:00Z","timestamp":1681257600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Wuxi Project of Science and Technology Development","award":["N20191001"],"award-info":[{"award-number":["N20191001"]}]},{"name":"Wuxi Project of Science and Technology Development","award":["N20192024)"],"award-info":[{"award-number":["N20192024)"]}]},{"name":"Wuxi Translational Medicine Research Special Funding Project","award":["ZZ003"],"award-info":[{"award-number":["ZZ003"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The prevalence of colorectal cancer (CRC) worldwide is a huge challenge to human health. Primary tumor locations found to impact prognosis and response to therapy. The important role of gut microbiota in the progression and treatment of CRC has led to many attempts of alleviating chemotherapy-induced adverse effects using microecologics. However, the underlying mechanism of the difference in the prognosis of different primary tumor locations and the synergistic effect of prebiotics on chemotherapy need to be further elucidated. This study aims to explore the differences in tumor microbiota and examine the effectiveness of xylooligosaccharides (XOS) on gut microbiota, adverse effects, and bioavailability of chemotherapy drugs in CRC patients at different primary tumor locations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This is a double-blinded, randomized, parallel controlled clinical trial. Participants with left-sided CRC (LSCRC,\n                      <jats:italic>n<\/jats:italic>\n                      = 50) and right-sided CC (RSCC,\n                      <jats:italic>n<\/jats:italic>\n                      = 50) will randomly allocated to prebiotic group (\n                      <jats:italic>n<\/jats:italic>\n                      = 25) or control group (\n                      <jats:italic>n<\/jats:italic>\n                      = 25) and will receive either a daily XOS (3 g\/day) or placebo, respectively, for 12 weeks. The primary outcomes will be the differences in the mucosa microbiota composition at different tumor locations and differences in gut microbiota composition, adverse effects, and blood concentration of capecitabine posttreatment. The secondary outcomes will include other blood indicators, short-chain fatty acids (SCFAs) concentration, quality of life, and mental health.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>This study will reveal the potential benefits of prebiotic for improving the gut microbiota composition, alleviating the adverse effects, and improving the efficacy of chemotherapy in patients with CRC. In addition, this study will provide data on the different distribution of tumor microbiota and the different changes of gut microbiota during treatment in LSCRC and RSCC, which may provide novel insights into personalized cancer treatment strategies based on primary tumor locations and gut microbiota in the future.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>\n                      Chinese Clinical Trial Registry (\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.chictr.org.cn\/\">www.chictr.org.cn<\/jats:ext-link>\n                      ): ChiCTR2100046237. Registered on 12 May 2021.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13063-023-07137-y","type":"journal-article","created":{"date-parts":[[2023,4,12]],"date-time":"2023-04-12T06:03:57Z","timestamp":1681279437000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Effects of prebiotic supplement on gut microbiota, drug bioavailability, and adverse effects in patients with colorectal cancer at different primary tumor locations receiving chemotherapy: study protocol for a randomized clinical trial"],"prefix":"10.1186","volume":"24","author":[{"given":"Ya","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowei","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanmin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bojian","family":"Fei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanqing","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huaxiang","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoping","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9495-8508","authenticated-orcid":false,"given":"Wei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianmin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,12]]},"reference":[{"key":"7137_CR1","first-page":"22","volume":"64","author":"M Groblewska","year":"2010","unstructured":"Groblewska M, Mroczko B, Szmitkowski M. The role of selected matrix metalloproteinases and their inhibitors in colorectal cancer development. Postepy Hig Med Dosw (Online). 2010;64:22\u201330.","journal-title":"Postepy Hig Med Dosw (Online)"},{"issue":"4","key":"7137_CR2","doi-asserted-by":"publisher","first-page":"259","DOI":"10.3322\/caac.21372","volume":"67","author":"MK Barton","year":"2017","unstructured":"Barton MK. Primary tumor location found to impact prognosis and response to therapy in patients with metastatic colorectal cancer. CA-Cancer J Clin. 2017;67(4):259\u201360.","journal-title":"CA-Cancer J Clin"},{"issue":"3","key":"7137_CR3","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA-Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA-Cancer J Clin"},{"issue":"8","key":"7137_CR4","doi-asserted-by":"publisher","first-page":"E457","DOI":"10.1016\/S1470-2045(17)30411-4","volume":"18","author":"J Kerr","year":"2017","unstructured":"Kerr J, Anderson C, Lippman SM. Physical activity, sedentary behaviour, diet, and cancer: an update and emerging new evidence. Lancet Oncol. 2017;18(8):E457\u201371.","journal-title":"Lancet Oncol"},{"issue":"6369","key":"7137_CR5","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1126\/science.aal5240","volume":"358","author":"S Bullman","year":"2017","unstructured":"Bullman S, Pedamallu CS, Sicinska E, Claney TE, Zhang XY, Cai DN, Neuberg D, Huang K, Guevara F, Nelson T, et al. Analysis of Fusobacterium persistence and antibiotic response in colorectal cancer. Science. 2017;358(6369):1443.","journal-title":"Science"},{"issue":"7802","key":"7137_CR6","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/s41586-020-2080-8","volume":"580","author":"C Pleguezuelos-Manzano","year":"2020","unstructured":"Pleguezuelos-Manzano C, Puschhof J, Huber AR, van Hoeck A, Wood HM, Nomburg J, Gurjao C, Manders F, Dalmasso G, Stege PB, et al. Mutational signature in colorectal cancer caused by genotoxic pks(+)E. coli. Nature. 2020;580(7802):269.","journal-title":"Nature"},{"issue":"3","key":"7137_CR7","doi-asserted-by":"publisher","first-page":"145","DOI":"10.3322\/caac.21601","volume":"70","author":"RL Siegel","year":"2020","unstructured":"Siegel RL, Miller KD, Goding Sauer A, Fedewa SA, Butterly LF, Anderson JC, Cercek A, Smith RA, Jemal A. Colorectal cancer statistics, 2020. CA Cancer J Clin. 2020;70(3):145\u201364.","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"7137_CR8","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1001\/jamaoncol.2016.3797","volume":"3","author":"S Tejpar","year":"2017","unstructured":"Tejpar S, Stintzing S, Ciardiello F, Tabernero J, Van Cutsem E, Beier F, Esser R, Lenz H-J, Heinemann V. Prognostic and predictive relevance of primary tumor location in patients with RAS wild-type metastatic colorectal cancer retrospective analyses of the CRYSTAL and FIRE-3 trials. JAMA Oncol. 2017;3(2):194\u2013201.","journal-title":"JAMA Oncol"},{"issue":"2","key":"7137_CR9","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1001\/jamaoncol.2016.4227","volume":"3","author":"F Petrelli","year":"2017","unstructured":"Petrelli F, Tomasello G, Borgonovo K, Ghidini M, Turati L, Dallera P, Passalacqua R, Sgroi G, Barni S. Prognostic survival associated with left-sided vs right-sided colon cancer a systematic review and meta-analysis. JAMA Oncol. 2017;3(2):211\u20139.","journal-title":"JAMA Oncol"},{"key":"7137_CR10","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.ejca.2016.10.007","volume":"70","author":"JW Holch","year":"2017","unstructured":"Holch JW, Ricard I, Stintzing S, Modest DP, Heinemann V. The relevance of primary tumour location in patients with metastatic colorectal cancer: a meta-analysis of first-line clinical trials. Eur J Cancer. 2017;70:87\u201398.","journal-title":"Eur J Cancer"},{"issue":"8","key":"7137_CR11","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1093\/annonc\/mdx175","volume":"28","author":"D Arnold","year":"2017","unstructured":"Arnold D, Lueza B, Douillard JY, Peeters M, Lenz HJ, Venook A, Heinemann V, Van Cutsem E, Pignon JP, Tabernero J, et al. Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials. Ann Oncol. 2017;28(8):1713\u201329.","journal-title":"Ann Oncol"},{"issue":"2","key":"7137_CR12","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.chom.2013.07.012","volume":"14","author":"MR Rubinstein","year":"2013","unstructured":"Rubinstein MR, Wang X, Liu W, Hao Y, Cai G, Han YW. Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin\/beta-catenin signaling via its FadA adhesin. Cell Host Microbe. 2013;14(2):195\u2013206.","journal-title":"Cell Host Microbe"},{"issue":"12","key":"7137_CR13","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1158\/2159-8290.CD-14-0501","volume":"4","author":"DR Donohoe","year":"2014","unstructured":"Donohoe DR, Holley D, Collins LB, Montgomery SA, Whitmore AC, Hillhouse A, Curry KP, Renner SW, Greenwalt A, Ryan EP, et al. A gnotobiotic mouse model demonstrates that dietary fiber protects against colorectal tumorigenesis in a microbiota- and butyrate-dependent manner. Cancer Discov. 2014;4(12):1387\u201397.","journal-title":"Cancer Discov"},{"issue":"4","key":"7137_CR14","doi-asserted-by":"publisher","first-page":"G223","DOI":"10.1152\/ajpgi.00212.2014","volume":"308","author":"V Stojanovska","year":"2015","unstructured":"Stojanovska V, Sakkal S, Nurgali K. Platinum-based chemotherapy: gastrointestinal immunomodulation and enteric nervous system toxicity. Am J Physiol Gastrointest Liver Physiol. 2015;308(4):G223\u201332.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"2","key":"7137_CR15","doi-asserted-by":"publisher","first-page":"E77","DOI":"10.1016\/S1470-2045(18)30952-5","volume":"20","author":"JL McQuade","year":"2019","unstructured":"McQuade JL, Daniel CR, Helmink BA, Wargo JA. Modulating the microbiome to improve therapeutic response in cancer. Lancet Oncol. 2019;20(2):E77\u201391.","journal-title":"Lancet Oncol"},{"issue":"2","key":"7137_CR16","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/nrd2505","volume":"7","author":"W Jia","year":"2008","unstructured":"Jia W, Li HK, Zhao LP, Nicholson JK. Gut microbiota: a potential new territory for drug targeting. Nat Rev Drug Discov. 2008;7(2):123\u20139.","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"7137_CR17","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.cell.2017.07.008","volume":"170","author":"TC Yu","year":"2017","unstructured":"Yu TC, Guo FF, Yu YN, Sun TT, Ma D, Han JX, Qian Y, Kryczek I, Sun DF, Nagarsheth N, et al. Fusobacterium nucleatum promotes chemoresistance to colorectal cancer by modulating autophagy. Cell. 2017;170(3):548.","journal-title":"Cell"},{"issue":"5","key":"7137_CR18","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1039\/C5FO00120J","volume":"6","author":"M Emorine","year":"2015","unstructured":"Emorine M, Septier C, Andriot I, Martin C, Salles C, Thomas-Danguin T. The ellagic acid-derived gut microbiota metabolite, urolithin A, potentiates the anticancer effects of 5-fluorouracil chemotherapy on human colon cancer cells. Food Funct. 2015;6(5):1460\u20139.","journal-title":"Food Funct"},{"issue":"7","key":"7137_CR19","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1016\/j.cell.2020.05.001","volume":"181","author":"B Javdan","year":"2020","unstructured":"Javdan B, Lopez JG, Chankhamjon P, Lee Y-CJ, Hull R, Wu Q, Wang X, Chatterjee S, Donia MS. Personalized mapping of drug metabolism by the human gut microbiome. Cell. 2020;181(7):1661.","journal-title":"Cell"},{"key":"7137_CR20","doi-asserted-by":"publisher","first-page":"983","DOI":"10.3389\/fmicb.2018.00983","volume":"9","author":"C-W Chang","year":"2018","unstructured":"Chang C-W, Liu C-Y, Lee H-C, Huang Y-H, Li L-H, Chiau J-SC, Wang T-E, Chu C-H, Shih S-C, Tsai T-H, et al. Lactobacillus casei variety rhamnosus probiotic preventively attenuates 5-fluorouracil\/oxaliplatin-induced intestinal injury in a syngeneic colorectal cancer model. Front Microbiol. 2018;9:983.","journal-title":"Front Microbiol"},{"issue":"8","key":"7137_CR21","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1038\/sj.bjc.6603990","volume":"97","author":"P Osterlund","year":"2007","unstructured":"Osterlund P, Ruotsalainen T, Korpela R, Saxelin M, Ollus A, Valta P, Kouri M, Elomaa I, Joensuu H. Lactobacillus supplementation for diarrhoea related to chemotherapy of colorectal cancer: a randomised study. Br J Cancer. 2007;97(8):1028\u201334.","journal-title":"Br J Cancer"},{"key":"7137_CR22","unstructured":"He-Lei LU, Qin HL. Randomized controlled clinical study on synbiotics improvement of postoperative adverse reactions to chemotherapy in patients with colorectal cancer. Shanghai J Prev Med.\u00a02019;31(10):799-802."},{"issue":"6","key":"7137_CR23","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1080\/10408398.2012.741082","volume":"56","author":"H Wang","year":"2016","unstructured":"Wang H, Geier MS, Howarth GS. Prebiotics: a potential treatment strategy for the chemotherapy-damaged gut? Crit Rev Food Sci Nutr. 2016;56(6):946\u201356.","journal-title":"Crit Rev Food Sci Nutr"},{"key":"7137_CR24","first-page":"1327","volume":"26","author":"J Peng","year":"2011","unstructured":"Peng J. Early enteral nutrition with prebiotic fiber supply in major abdominal surgery versus conventional enteral nutrition: a prospective controlled trial. West China Med J. 2011;26:1327\u201330.","journal-title":"West China Med J"},{"issue":"none","key":"7137_CR25","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.biortech.2011.10.083","volume":"115","author":"D Chapla","year":"2012","unstructured":"Chapla D, Pandit P, Shah A. Production of xylooligosaccharides from corncob xylan by fungal xylanase and their utilization by probiotics. Bioresour Technol. 2012;115(none):215\u201321.","journal-title":"Bioresour Technol"},{"issue":"14","key":"7137_CR26","doi-asserted-by":"publisher","first-page":"7171","DOI":"10.1016\/j.biortech.2011.03.110","volume":"102","author":"H Yang","year":"2011","unstructured":"Yang H, Wang K, Song X, Feng X. Production of xylooligosaccharides by xylanase from Pichia stipitis based on xylan preparation from triploid Populas tomentosa. Bioresour Technol. 2011;102(14):7171\u20136.","journal-title":"Bioresour Technol"},{"issue":"7","key":"7137_CR27","doi-asserted-by":"publisher","first-page":"e0159223","DOI":"10.1371\/journal.pone.0159223","volume":"11","author":"S Hald","year":"2016","unstructured":"Hald S, Schioldan AG, Moore ME, Dige A, L\u00e6rke HN, Agnholt J, Knudsen KEB, Hermansen K, Marco ML, Gregersen SJPO. Effects of arabinoxylan and resistant starch on intestinal microbiota and short-chain fatty acids in subjects with metabolic syndrome: a randomised crossover study. PLoS One. 2016;11(7):e0159223.","journal-title":"PLoS One"},{"issue":"OCT.1","key":"7137_CR28","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.foodchem.2017.03.149","volume":"232","author":"M Nieto-Dominguez","year":"2017","unstructured":"Nieto-Dominguez M, De Eugenio LI, York-Duran MJ, Rodriguez-Colinas B, Plou FJ, Chenoll E, Pardo E, Codoner F, Jesus Martinez M. Prebiotic effect of xylooligosaccharides produced from birchwood xylan by a novel fungal GH11 xylanase. Food Chem. 2017;232(OCT.1):105.","journal-title":"Food Chem"},{"issue":"2\u20133","key":"7137_CR29","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/j.foodchem.2012.11.017","volume":"138","author":"T Iida","year":"2013","unstructured":"Iida T, Yamada T, Hayashi N, Okuma K, Izumori K, Ishii R, Matsuo T. Reduction of abdominal fat accumulation in rats by 8-week ingestion of a newly developed sweetener made from high fructose corn syrup. Food Chem. 2013;138(2\u20133):781\u20135.","journal-title":"Food Chem"},{"issue":"3","key":"7137_CR30","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1016\/j.fsi.2013.06.014","volume":"35","author":"Z Geraylou","year":"2013","unstructured":"Geraylou Z, Souffreau C, Rurangwa E, De Meester L, Courtin CM, Delcour JA, Buyse J, Ollevier F. Effects of dietary arabinoxylan-oligosaccharides (AXOS) and endogenous probiotics on the growth performance, non-specific immunity and gut microbiota of juvenile Siberian sturgeon (Acipenser baerii). Fish Shellfish Immunol. 2013;35(3):766\u201375.","journal-title":"Fish Shellfish Immunol"},{"issue":"8","key":"7137_CR31","doi-asserted-by":"publisher","first-page":"919","DOI":"10.3109\/09637486.2015.1064869","volume":"66","author":"Z Li","year":"2015","unstructured":"Li Z, Summanen PH, Komoriya T. In vitro study of the prebiotic xylooligosaccharide (XOS) on the growth of Bifidobacterium spp and Lactobacillus spp. Int J Food Sci Nutr. 2015;66(8):919\u201322.","journal-title":"Int J Food Sci Nutr"},{"issue":"6","key":"7137_CR32","doi-asserted-by":"publisher","first-page":"445","DOI":"10.3177\/jnsv.51.445","volume":"51","author":"I Tateyama","year":"2005","unstructured":"Tateyama I, Hashii K, Johno I, Iino T, Hirai K, Suwa Y, Kiso Y. Effect of xylooligosaccharide intake on severe constipation in pregnant women. J Nutr Sci Vitaminol. 2005;51(6):445\u20138.","journal-title":"J Nutr Sci Vitaminol"},{"issue":"1","key":"7137_CR33","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.foodres.2012.11.021","volume":"51","author":"A Carvalho","year":"2013","unstructured":"Carvalho A, Silva D, Pastore GM, Neto P. Xylo-oligosaccharides from lignocellulosic materials: Chemical structure, health benefits and production by chemical and enzymatic hydrolysis. Food Res Int. 2013;51(1):75\u201385.","journal-title":"Food Res Int"},{"key":"7137_CR34","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.foodhyd.2013.07.022","volume":"42","author":"M Mendis","year":"2014","unstructured":"Mendis M, Simsek S. Arabinoxylans and human health. Food Hydrocoll. 2014;42:239\u201343.","journal-title":"Food Hydrocoll"},{"issue":"2","key":"7137_CR35","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.physbeh.2007.11.045","volume":"94","author":"JJ Volman","year":"2008","unstructured":"Volman JJ, Ramakers JD, Plat J. Dietary modulation of immune function by beta-glucans. Physiol Behav. 2008;94(2):276\u201384.","journal-title":"Physiol Behav"},{"issue":"8","key":"7137_CR36","doi-asserted-by":"publisher","first-page":"605","DOI":"10.3109\/15376516.2012.706837","volume":"22","author":"Y Gao","year":"2012","unstructured":"Gao Y, Zhang S, Li C, Xiao L, Shen J, Yin J. Acute and subchronic toxicity of xylo-oligosaccharide in mice and rats. Toxicol Mech Methods. 2012;22(8):605\u201310.","journal-title":"Toxicol Mech Methods"},{"issue":"7","key":"7137_CR37","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1351\/pac200274071253","volume":"74","author":"T Oku","year":"2002","unstructured":"Oku T, Nakamura AS. Digestion, absorption, fermentation, and metabolism of functional sugar substitutes and their available energy. Pure Appl Chem. 2002;74(7):1253\u201361.","journal-title":"Pure Appl Chem"},{"issue":"7","key":"7137_CR38","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.4014\/jmb.1501.01022","volume":"25","author":"X Yu","year":"2015","unstructured":"Yu X, Yin J, Li L, Luan C, Zhang J, Zhao C, Li S. Prebiotic potential of xylooligosaccharides derived from corn cobs and their in vitro antioxidant activity when combined with Lactobacillus. J Microbiol Biotechnol. 2015;25(7):1084\u201392.","journal-title":"J Microbiol Biotechnol"},{"key":"7137_CR39","doi-asserted-by":"publisher","first-page":"e7586","DOI":"10.1136\/bmj.e7586","volume":"346","author":"A-W Chan","year":"2013","unstructured":"Chan A-W, Tetzlaff JM, Gotzsche PC, Altman DG, Mann H, Berlin JA, Dickersin K, Hrobjartsson A, Schulz KF, Parulekar WR, et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. Bmj-Br Med J. 2013;346:e7586.","journal-title":"Bmj-Br Med J"},{"issue":"1","key":"7137_CR40","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ad.2019.05.009","volume":"112","author":"A Freites-Martinez","year":"2021","unstructured":"Freites-Martinez A, Santana N, Arias-Santiago S, Viera A. Using the Common Terminology Criteria for Adverse Events (CTCAE - Version 50) to evaluate the severity of adverse events of anticancer therapies. Actas Dermosifiliogr. 2021;112(1):90\u20132.","journal-title":"Actas Dermosifiliogr"},{"issue":"4","key":"7137_CR41","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1007\/s00520-019-04999-4","volume":"28","author":"HA Blackwood","year":"2020","unstructured":"Blackwood HA, Hall CC, Balstad TR. A systematic review examining nutrition support interventions in patients with incurable cancer. Support Care Cancer. 2020;28(4):1877\u201389.","journal-title":"Support Care Cancer"},{"key":"7137_CR42","unstructured":"Yang Y, GW X. Pan: China food composition (Book 1.2nd Edition): Beijing Medical Univ. Press; 2009:364."},{"issue":"2","key":"7137_CR43","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1023\/A:1008981520920","volume":"9","author":"H Zhao","year":"2000","unstructured":"Zhao H, Kanda K. Translation and validation of the Standard Chinese version of the EORTC QLQ-C30. Qual Life Res. 2000;9(2):129\u201337.","journal-title":"Qual Life Res"},{"issue":"4","key":"7137_CR44","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1093\/annonc\/mds575","volume":"24","author":"J Walker","year":"2013","unstructured":"Walker J, Hansen CH, Martin P, Sawhney A, Thekkumpurath P, Beale C, Symeonides S, Wall L, Murray G, Sharpe M. Prevalence of depression in adults with cancer: a systematic review. Ann Oncol. 2013;24(4):895\u2013900.","journal-title":"Ann Oncol"},{"issue":"3","key":"7137_CR45","doi-asserted-by":"publisher","first-page":"411","DOI":"10.3390\/ijerph16030411","volume":"16","author":"Y-N Peng","year":"2019","unstructured":"Peng Y-N, Huang M-L, Kao C-H. Prevalence of depression and anxiety in colorectal cancer patients: a literature review. Int J Environ Res Public Health. 2019;16(3):411.","journal-title":"Int J Environ Res Public Health"},{"issue":"12","key":"7137_CR46","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1136\/gutjnl-2015-310101","volume":"65","author":"K Mima","year":"2016","unstructured":"Mima K, Nishihara R, Qian ZR, Cao Y, Sukawa Y, Nowak JA, Yang J, Dou R, Masugi Y, Song M, et al. Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis. Gut. 2016;65(12):1973\u201380.","journal-title":"Gut"},{"issue":"6","key":"7137_CR47","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/nrgastro.2017.20","volume":"14","author":"JL Alexander","year":"2017","unstructured":"Alexander JL, Wilson ID, Teare J, Marchesi JR, Nicholson JK, Kinross JM. Gut microbiota modulation of chemotherapy efficacy and toxicity. Nat Rev Gastroenterol Hepatol. 2017;14(6):356\u201365.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"10","key":"7137_CR48","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1093\/annonc\/mdu106","volume":"25","author":"MG Redman","year":"2014","unstructured":"Redman MG, Ward EJ, Phillips RS. The efficacy and safety of probiotics in people with cancer: a systematic review. Ann Oncol. 2014;25(10):1919\u201329.","journal-title":"Ann Oncol"},{"key":"7137_CR49","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.4161\/cbt.6.9.4622","volume":"6","author":"J Bowen","year":"2007","unstructured":"Bowen J, Stringer A, Gibson R, Yeoh A, Hannam S, Keefe D. VSL#3 Probiotic treatment reduces chemotherapy-induced diarrhoea and weight loss. Cancer Biol Ther. 2007;6:1449\u201354.","journal-title":"Cancer Biol Ther"},{"issue":"1","key":"7137_CR50","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.clnu.2015.11.008","volume":"36","author":"M Motoori","year":"2017","unstructured":"Motoori M, Yano M, Miyata H, Sugimura K, Saito T, Omori T, Fujiwara Y, Miyoshi N, Akita H, Gotoh K, et al. Randomized study of the effect of synbiotics during neoadjuvant chemotherapy on adverse events in esophageal cancer patients. Clin Nutr. 2017;36(1):93\u20139.","journal-title":"Clin Nutr"},{"issue":"1","key":"7137_CR51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1207\/S15327914NC381_1","volume":"38","author":"HS Taper","year":"2000","unstructured":"Taper HS, Roberfroid MB. Nontoxic potentiation of cancer chemotherapy by dietary oligofructose or inulin. Nutr Cancer Int J. 2000;38(1):1\u20135.","journal-title":"Nutr Cancer Int J"},{"issue":"1","key":"7137_CR52","first-page":"201","volume":"19","author":"HS Taper","year":"2005","unstructured":"Taper HS, Roberfroid MB. Possible adjuvant cancer therapy by two prebioties - inulin or oligofructose. In Vivo. 2005;19(1):201\u20134.","journal-title":"In Vivo"},{"issue":"6","key":"7137_CR53","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1093\/jn\/125.6.1401","volume":"125","author":"GR Gibson","year":"1995","unstructured":"Gibson GR, Roberfroid MB. Dietary modulation of the human colonic microbiota - introducing the concept of prebiotics. J Nutr. 1995;125(6):1401\u201312.","journal-title":"J Nutr"},{"issue":"1","key":"7137_CR54","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1111\/j.1541-4337.2010.00135.x","volume":"10","author":"AA Aachary","year":"2011","unstructured":"Aachary AA, Prapulla SG. Xylooligosaccharides (XOS) as an emerging prebiotic: microbial synthesis, utilization, structural characterization, bioactive properties, and applications. Compr Rev Food Sci Food Saf. 2011;10(1):2\u201316.","journal-title":"Compr Rev Food Sci Food Saf"},{"issue":"5","key":"7137_CR55","doi-asserted-by":"publisher","first-page":"396","DOI":"10.3177\/jnsv.54.396","volume":"54","author":"WH-H Sheu","year":"2008","unstructured":"Sheu WH-H, Lee IT, Chen W, Chan Y-C. Effects of xylooligosaccharides in type 2 diabetes mellitus. J Nutr Sci Vitaminol. 2008;54(5):396\u2013401.","journal-title":"J Nutr Sci Vitaminol"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-023-07137-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-023-07137-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-023-07137-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,12]],"date-time":"2023-04-12T07:15:16Z","timestamp":1681283716000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-023-07137-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,12]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["7137"],"URL":"https:\/\/doi.org\/10.1186\/s13063-023-07137-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-907838\/v1","asserted-by":"object"}]},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,12]]},"assertion":[{"value":"14 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study protocol (version 1, May 8, 2021) has been approved by an ethical committee of the Affiliated Hospital of Jiangnan University, Wuxi, China (LS2021026), and was registered at the Chinese Clinical Trial Registry (\n                      \n                      , ChiCTR2100046237). Informed consent will be voluntarily signed by individuals who agree to participate in this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"A dissemination policy concerning the statistical data will be implemented to ensure that the official statistics are consistent, reliable, and comparable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Dissemination policy"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"268"}}